(CLN) Clariant - Ratings and Ratios
Care Chemicals, Catalysis, Adsorbents, Additives, Specialty Chemicals
Description: CLN Clariant
Clariant AG is a leading global specialty chemicals company with a diverse portfolio of products and services across various industries, including personal care, home care, agriculture, coatings, adhesives, and more. The companys three main business segments - Care Chemicals, Catalysis, and Adsorbents and Additives - cater to a broad range of applications, from consumer goods to industrial processes.
From a business perspective, Clariants strengths lie in its ability to provide innovative, high-performance solutions that meet the evolving needs of its customers. The companys extensive product portfolio, combined with its global presence, enables it to capitalize on emerging trends and growth opportunities in various regions. Key Performance Indicators (KPIs) to watch include revenue growth, segmental profitability, and return on invested capital (ROIC). Notably, Clariants focus on sustainability and innovation is likely to drive long-term value creation.
In terms of financial health, Clariants market capitalization stands at approximately CHF 2.79 billion, with a forward P/E ratio of 12.14, indicating a relatively reasonable valuation. The companys return on equity (RoE) of 11.20% suggests a decent level of profitability. To further assess Clariants investment potential, its essential to monitor its debt-to-equity ratio, interest coverage, and cash flow generation capabilities. A thorough analysis of these metrics will provide a more comprehensive understanding of the companys financial stability and growth prospects.
From a strategic perspective, Clariants ability to navigate the complex landscape of specialty chemicals will depend on its capacity to innovate, optimize its operations, and respond to shifting market dynamics. As the company continues to evolve, investors should keep a close eye on its progress in areas such as digitalization, sustainability, and customer-centricity, as these factors will likely play a crucial role in driving long-term success.
CLN Stock Overview
| Market Cap in USD | 3,411m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
CLN Stock Ratings
| Growth Rating | -73.2% |
| Fundamental | 53.6% |
| Dividend Rating | 12.5% |
| Return 12m vs S&P 500 | -45.1% |
| Analyst Rating | - |
CLN Dividends
| Dividend Yield 12m | 4.71% |
| Yield on Cost 5y | 2.74% |
| Annual Growth 5y | -31.30% |
| Payout Consistency | 70.9% |
| Payout Ratio | 68.9% |
CLN Growth Ratios
| Growth Correlation 3m | -51.8% |
| Growth Correlation 12m | -90.2% |
| Growth Correlation 5y | -86.4% |
| CAGR 5y | -11.73% |
| CAGR/Max DD 5y | -0.20 |
| Sharpe Ratio 12m | -1.60 |
| Alpha | -48.60 |
| Beta | 0.762 |
| Volatility | 28.70% |
| Current Volume | 613.8k |
| Average Volume 20d | 670.8k |
| Stop Loss | 7.9 (-3.9%) |
| Signal | -1.69 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (270.0m TTM) > 0 and > 6% of Revenue (6% = 368.0m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.21% (prev 14.35%; Δ -5.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 566.0m > Net Income 270.0m (YES >=105%, WARN >=100%) |
| Net Debt (1.50b) to EBITDA (621.0m) ratio: 2.41 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (328.3m) change vs 12m ago -0.17% (target <= -2.0% for YES) |
| Gross Margin 31.39% (prev 27.42%; Δ 3.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 109.9% (prev 81.86%; Δ 28.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.79 (EBITDA TTM 621.0m / Interest Expense TTM 142.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.73
| (A) 0.10 = (Total Current Assets 2.11b - Total Current Liabilities 1.55b) / Total Assets 5.82b |
| (B) 0.52 = Retained Earnings (Balance) 3.00b / Total Assets 5.82b |
| (C) 0.07 = EBIT TTM 396.0m / Avg Total Assets 5.58b |
| (D) 0.88 = Book Value of Equity 3.45b / Total Liabilities 3.90b |
| Total Rating: 3.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 53.59
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 5.48% = 2.74 |
| 3. FCF Margin 3.38% = 0.84 |
| 4. Debt/Equity 0.71 = 2.25 |
| 5. Debt/Ebitda 2.19 = -0.37 |
| 6. ROIC - WACC 1.17% = 1.46 |
| 7. RoE 12.55% = 1.05 |
| 8. Rev. Trend -92.60% = -4.63 |
| 9. Rev. CAGR -8.94% = -1.49 |
| 10. EPS Trend 29.62% = 0.74 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CLN shares?
Over the past week, the price has changed by -1.97%, over one month by -4.48%, over three months by -7.23% and over the past year by -35.79%.
Is Clariant a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLN is around 6.69 CHF . This means that CLN is currently overvalued and has a potential downside of -18.61%.
Is CLN a buy, sell or hold?
What are the forecasts/targets for the CLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.1 | 35.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 7.3 | -11.1% |
CLN Fundamental Data Overview
Market Cap CHF = 2.73b (2.73b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 314.0m CHF (last quarter)
P/E Trailing = 24.5
P/E Forward = 11.4548
P/S = 0.6731
P/B = 1.4164
P/EG = 0.9016
Beta = 0.594
Revenue TTM = 6.13b CHF
EBIT TTM = 396.0m CHF
EBITDA TTM = 621.0m CHF
Long Term Debt = 1.36b CHF (from longTermDebt, last quarter)
Short Term Debt = unknown (0.0)
Debt = 1.36b CHF (Calculated: Short Term 0.0 + Long Term 1.36b)
Net Debt = 1.50b CHF (from netDebt column, last fiscal year)
Enterprise Value = 3.78b CHF (2.73b + Debt 1.36b - CCE 314.0m)
Interest Coverage Ratio = 2.79 (Ebit TTM 396.0m / Interest Expense TTM 142.0m)
FCF Yield = 5.48% (FCF TTM 207.0m / Enterprise Value 3.78b)
FCF Margin = 3.38% (FCF TTM 207.0m / Revenue TTM 6.13b)
Net Margin = 4.40% (Net Income TTM 270.0m / Revenue TTM 6.13b)
Gross Margin = 31.39% ((Revenue TTM 6.13b - Cost of Revenue TTM 4.21b) / Revenue TTM)
Tobins Q-Ratio = 1.10 (Enterprise Value 3.78b / Book Value Of Equity 3.45b)
Interest Expense / Debt = 1.55% (Interest Expense 21.0m / Debt 1.36b)
Taxrate = 24.32% (from yearly Income Tax Expense: 90.0m / 370.0m)
NOPAT = 299.7m (EBIT 396.0m * (1 - 24.32%))
Current Ratio = 1.36 (Total Current Assets 2.11b / Total Current Liabilities 1.55b)
Debt / Equity = 0.71 (Debt 1.36b / last Quarter total Stockholder Equity 1.91b)
Debt / EBITDA = 2.19 (Net Debt 1.50b / EBITDA 621.0m)
Debt / FCF = 6.57 (Debt 1.36b / FCF TTM 207.0m)
Total Stockholder Equity = 2.15b (last 4 quarters mean)
RoA = 4.64% (Net Income 270.0m, Total Assets 5.82b )
RoE = 12.55% (Net Income TTM 270.0m / Total Stockholder Equity 2.15b)
RoCE = 11.28% (Ebit 396.0m / (Equity 2.15b + L.T.Debt 1.36b))
RoIC = 7.45% (NOPAT 299.7m / Invested Capital 4.02b)
WACC = 6.28% (E(2.73b)/V(4.09b) * Re(8.82%)) + (D(1.36b)/V(4.09b) * Rd(1.55%) * (1-Tc(0.24)))
Shares Correlation 5-Years: -70.0 | Cagr: -0.22%
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 67.02% ; FCFE base≈215.8m ; Y1≈141.7m ; Y5≈64.8m
Fair Price DCF = 3.42 (DCF Value 1.12b / Shares Outstanding 328.3m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -92.60 | Revenue CAGR: -8.94%
Rev Growth-of-Growth: 18.42
EPS Correlation: 29.62 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -116.3